Leonel Villa-Villegas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonel Villa-Villegas has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Zúñiga-Ramírez
Movement Disorders and Neurodegenerative Diseases Unit, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara, Mexico
4 shared publications Carlos Eduardo Piña-Avilés
Department of Genetics, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara, Mexico
3 shared publications- Luz Gabriela Lira-Jaime
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Movement Disorders and Neurodegenerative Diseases Unit, Guadalajara, Jalisco, México
3 shared publications - Biagio David González-Ruffino
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Movement Disorders and Neurodegenerative Diseases Unit, Guadalajara, Jalisco, México
2 shared publications - Katia Carmina Farías-Moreno
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Movement Disorders and Neurodegenerative Diseases Unit, Guadalajara, Jalisco, México
2 shared publications - Roberto Leal-Ortega
Department of Neurology, Hospital Faro del Mayab, Mérida Yucatán, México
2 shared publications
Latest Publications
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6)
Cerebrotendinous Xanthomatosis
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6)
Cerebrotendinous Xanthomatosis
- Open Access
- 13 August 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (10) , 001-008
Epidemiology and clinical features of movement disorders in a Mexican Mestizo cohort: a 10-year tertiary-center study
Movement disorders comprise a heterogeneous spectrum of neurological conditions characterized by impaired motor control. Limited epidemiological data exist for Latin American populations, particularly for Mexican Mestizos. To characterize the epidemiological profile and clinical features of movement disorders in a large cohort of Mexican Mestizo patients evaluated at a public tertiary referral center in western Mexico. We conducted a 10-year retrospective cohort study (2012–2022) analyzing medical records from the Movement Disorders and Neurodegenerative Diseases Unit at the Hospital Civil de Guadalajara, a public tertiary university hospital from the western region of Mexico. Inclusion criteria were confirmed movement disorder diagnosis and a minimum of two clinical evaluations. Binary logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CIs). Among 1,830 records (mean age 58.5 ± 17.0 years, 53.9% female, all self-identified as Mexican Mestizo), hypokinetic disorders comprised 63.9% (n = 1,170) and hyperkinetic disorders 36.1% (n = 660). Parkinsonism (63.6%, n = 1,163) and tremor (11.3%, n = 206) were the most frequent subtypes. Hypokinetic disorders were associated with older age (64.2 ± 12.8 vs. 48.5 ± 18.9 years, p < 0.001), hypertension (OR = 2.29; 1.78–2.95; p = 0.001), and smoking (OR = 1.51; 1.13–2.03; p = 0.005). Hyperkinetic disorders were associated with male sex (OR = 1.47; 1.19–1.82; p < 0.001), family history (OR = 1.92; 1.49–2.47; p < 0.001), and functional presentations (OR = 11.0; 5.53–22.14; p < 0.001). This is the largest reported Mexican Mestizo cohort with movement disorders evaluated in a single public tertiary center. Findings reveal distinct demographic and clinical patterns and may inform integrated cardiovascular–neurological care models, screening protocols, and resource allocation within the Mexican public health system.
- 13 August 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (10) , 001-008
Open AccessEpidemiology and clinical features of movement disorders in a Mexican Mestizo cohort: a 10-year tertiary-center study
Movement disorders comprise a heterogeneous spectrum of neurological conditions characterized by impaired motor control. Limited epidemiological data exist for Latin American populations, particularly for Mexican Mestizos. To characterize the epidemiological profile and clinical features of movement disorders in a large cohort of Mexican Mestizo patients evaluated at a public tertiary referral center in western Mexico. We conducted a 10-year retrospective cohort study (2012–2022) analyzing medical records from the Movement Disorders and Neurodegenerative Diseases Unit at the Hospital Civil de Guadalajara, a public tertiary university hospital from the western region of Mexico. Inclusion criteria were confirmed movement disorder diagnosis and a minimum of two clinical evaluations. Binary logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CIs). Among 1,830 records (mean age 58.5 ± 17.0 years, 53.9% female, all self-identified as Mexican Mestizo), hypokinetic disorders comprised 63.9% (n = 1,170) and hyperkinetic disorders 36.1% (n = 660). Parkinsonism (63.6%, n = 1,163) and tremor (11.3%, n = 206) were the most frequent subtypes. Hypokinetic disorders were associated with older age (64.2 ± 12.8 vs. 48.5 ± 18.9 years, p < 0.001), hypertension (OR = 2.29; 1.78–2.95; p = 0.001), and smoking (OR = 1.51; 1.13–2.03; p = 0.005). Hyperkinetic disorders were associated with male sex (OR = 1.47; 1.19–1.82; p < 0.001), family history (OR = 1.92; 1.49–2.47; p < 0.001), and functional presentations (OR = 11.0; 5.53–22.14; p < 0.001). This is the largest reported Mexican Mestizo cohort with movement disorders evaluated in a single public tertiary center. Findings reveal distinct demographic and clinical patterns and may inform integrated cardiovascular–neurological care models, screening protocols, and resource allocation within the Mexican public health system.
- 22 September 2025
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 53 (5) , 1-7
Prodromal Association of Non-Motor Symptomatology in Adults With Neurodegenerative Diseases
Background: Early diagnosis of neurodegenerative diseases (NDs) is a priority with the advent of disease-modifying therapies. The study of prodromal non-motor symptoms (NMS) in ND could help guide early diagnosis, facilitating adequate treatment. The primary objective of this study was to determine the prodromal association between NMS and ND. Methods: A retrospective cohort study was planned. Records of subjects attending the movement disorders and NDs unit from Hospital Civil de Guadalajara “Fray Antonio Alcalde,” from 2012 to January 2025, were evaluated. Subjects with NMSQuest questionnaire in ND were included. Descriptive and inferential parametric statistics (Student’s t-test for independent samples and ANOVA) were used, and odds ratios (OD) with 95% confidence interval were calculated using binary logistic regression. A p value < 0.05 was considered significant. Results: The most frequent prodromal NMS in ND were depression, constipation, insomnia, anxiety and pain. There was an average of 7.7 ± 7.6 years of prodromal NMS prior to the diagnosis of ND. Prodromal depression [OR 1.9 (1.1–3.5 p < 0.001) and confusion/delusional thoughts [OR 7.2 (1.3–39.2) p = 0.02] were associated with dementia (time onset prior to diagnosis 9.9 ± 12.2 and 5.5 ± 9.7 years, respectively). Prodromal restless legs syndrome was associated with movement disorders [OR 3.3 (1.1–9.7) p = 0.02] (time onset 4.7 ± 6.9 years prior to diagnosis). Conclusion: Evidence points to a potential association of prodromal NMS in ND. Prospective studies are required to confirm and characterize the association between prodromal NMS and ND, as their early identification may contribute to the timely diagnosis of ND.
- 22 September 2025
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 53 (5) , 1-7
Prodromal Association of Non-Motor Symptomatology in Adults With Neurodegenerative Diseases
Background: Early diagnosis of neurodegenerative diseases (NDs) is a priority with the advent of disease-modifying therapies. The study of prodromal non-motor symptoms (NMS) in ND could help guide early diagnosis, facilitating adequate treatment. The primary objective of this study was to determine the prodromal association between NMS and ND. Methods: A retrospective cohort study was planned. Records of subjects attending the movement disorders and NDs unit from Hospital Civil de Guadalajara “Fray Antonio Alcalde,” from 2012 to January 2025, were evaluated. Subjects with NMSQuest questionnaire in ND were included. Descriptive and inferential parametric statistics (Student’s t-test for independent samples and ANOVA) were used, and odds ratios (OD) with 95% confidence interval were calculated using binary logistic regression. A p value < 0.05 was considered significant. Results: The most frequent prodromal NMS in ND were depression, constipation, insomnia, anxiety and pain. There was an average of 7.7 ± 7.6 years of prodromal NMS prior to the diagnosis of ND. Prodromal depression [OR 1.9 (1.1–3.5 p < 0.001) and confusion/delusional thoughts [OR 7.2 (1.3–39.2) p = 0.02] were associated with dementia (time onset prior to diagnosis 9.9 ± 12.2 and 5.5 ± 9.7 years, respectively). Prodromal restless legs syndrome was associated with movement disorders [OR 3.3 (1.1–9.7) p = 0.02] (time onset 4.7 ± 6.9 years prior to diagnosis). Conclusion: Evidence points to a potential association of prodromal NMS in ND. Prospective studies are required to confirm and characterize the association between prodromal NMS and ND, as their early identification may contribute to the timely diagnosis of ND.
- Open Access
- 5 September 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1)
“Deep Brain Stimulation of the Ventral Intermediate Nucleus of the Thalamus for Tremor in Polr3a-Related Tremor-ataxia Syndrome: A Two-case Report”
Clinical Vignette: RNA polymerase III subunit A (POLR3A) related disorders are a group of heterogeneous diseases with a recessive autosomic inheritance. These disorders manifest with distinct clinical features like ataxia, spasticity, hypodontia, hypogonadism, mental retardation and progressive motor decline. Clinical Dilemma: POLR3A gene mutation can manifest with parkinsonism, dystonia, ataxia and tremor. Deep brain stimulation (DBS) might be effective for motor symptoms. Choosing the best DBS target is essential for successful treatment. Case reports and Clinical Solution: Two subjects with a predominant tremorous syndrome due to POLR3A gene mutation with no response to pharmacological treatment underwent DBS at ventral intermediate nuclei (Vim DBS) of thalamus, with significant improvement in tremor. Gap in Knowledge: Tremor in POLR3A gene mutation could respond to Vim DBS.
- 5 September 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1)
Open Access“Deep Brain Stimulation of the Ventral Intermediate Nucleus of the Thalamus for Tremor in Polr3a-Related Tremor-ataxia Syndrome: A Two-case Report”
Clinical Vignette: RNA polymerase III subunit A (POLR3A) related disorders are a group of heterogeneous diseases with a recessive autosomic inheritance. These disorders manifest with distinct clinical features like ataxia, spasticity, hypodontia, hypogonadism, mental retardation and progressive motor decline. Clinical Dilemma: POLR3A gene mutation can manifest with parkinsonism, dystonia, ataxia and tremor. Deep brain stimulation (DBS) might be effective for motor symptoms. Choosing the best DBS target is essential for successful treatment. Case reports and Clinical Solution: Two subjects with a predominant tremorous syndrome due to POLR3A gene mutation with no response to pharmacological treatment underwent DBS at ventral intermediate nuclei (Vim DBS) of thalamus, with significant improvement in tremor. Gap in Knowledge: Tremor in POLR3A gene mutation could respond to Vim DBS.
- Open Access
- 22 July 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1) , 32
Deep Brain Stimulation in Leigh-Like Syndrome Due to DNM1 Pathogenic Variant
Clinical vignette: Leigh syndrome (LS) and Leigh-like syndromes (LLS), now collectively referred to as Leigh Syndrome Spectrum (LSS), encompass a wide range of clinical manifestations, including epilepsy, neurodevelopmental delay, and movement disorders such as ataxia, chorea, and dystonia. Although rare, LSS can present atypical symptoms in certain cases. The primary etiological cause of LSS is genetic, resulting from mitochondrial alterations. Clinical dilemma: Hyperkinesias in LSS or other mitochondrial disorders can be disabling, leading to a significant reduction in the patient’s quality of life. Clinical solution: Globus pallidum deep brain stimulation (GPi-DBS) surgery is an effective treatment for hyperkinesias, such as chorea, and dystonia, caused by mitochondrial defects. Gap in knowledge: Pathogenic DNM1-related mitochondrial disorders with Leigh syndrome phenotype may show long-term improvement of hyperkinetic movements after GPi-DBS.
- 22 July 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1) , 32
Open AccessDeep Brain Stimulation in Leigh-Like Syndrome Due to DNM1 Pathogenic Variant
Clinical vignette: Leigh syndrome (LS) and Leigh-like syndromes (LLS), now collectively referred to as Leigh Syndrome Spectrum (LSS), encompass a wide range of clinical manifestations, including epilepsy, neurodevelopmental delay, and movement disorders such as ataxia, chorea, and dystonia. Although rare, LSS can present atypical symptoms in certain cases. The primary etiological cause of LSS is genetic, resulting from mitochondrial alterations. Clinical dilemma: Hyperkinesias in LSS or other mitochondrial disorders can be disabling, leading to a significant reduction in the patient’s quality of life. Clinical solution: Globus pallidum deep brain stimulation (GPi-DBS) surgery is an effective treatment for hyperkinesias, such as chorea, and dystonia, caused by mitochondrial defects. Gap in knowledge: Pathogenic DNM1-related mitochondrial disorders with Leigh syndrome phenotype may show long-term improvement of hyperkinetic movements after GPi-DBS.